Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2006-09-11
2010-06-01
Kam, Chih-Min (Department: 1656)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S236100, C424S009100, C514S002600, C514S012200, C530S350000, C435S007100, C435S006120, C435S069100, C435S325000, C435S368000, C435S371000
Reexamination Certificate
active
07727538
ABSTRACT:
A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma and other clinical conditions involving COPD, comprises administering a compound that inhibits exocytosis in mucus secreting cells or neurones that control or direct mucus secretion. Also described is a compound, for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secretion by mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.
REFERENCES:
patent: 4792447 (1988-12-01), Uhr et al.
patent: 4873346 (1989-10-01), Anderson
patent: 5668255 (1997-09-01), Murphy
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6395513 (2002-05-01), Foster et al.
patent: 6461617 (2002-10-01), Shone et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 6962703 (2005-11-01), Foster et al.
patent: 7052702 (2006-05-01), Duggan et al.
patent: 7192596 (2007-03-01), Shone et al.
patent: 2003/0049264 (2003-03-01), Foster et al.
patent: 2003/0147895 (2003-08-01), Shone et al.
patent: 2003/0166238 (2003-09-01), Shone et al.
patent: 197 35 105 (1999-03-01), None
patent: 0 673 938 (1995-09-01), None
patent: WO 91/09871 (1991-07-01), None
patent: WO 92/15327 (1992-09-01), None
patent: WO 93/04191 (1993-03-01), None
patent: WO 93/15766 (1993-08-01), None
patent: WO 94/21300 (1994-09-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO 95/28171 (1995-10-01), None
patent: WO 95/33850 (1995-12-01), None
patent: WO 96/12802 (1996-05-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO 97/13410 (1997-04-01), None
patent: WO 98/07684 (1998-02-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 98/08540 (1998-03-01), None
patent: WO 99/58571 (1999-11-01), None
patent: WO 00/04926 (2000-02-01), None
patent: WO 00/10598 (2000-03-01), None
Bizzini, B., “Investigation of the Mode of Action of Tetanus Toxin with the Aid of Hybrid Molecules Consisting in Part of Tetanus Toxin-Derived Fragments,”Bacterial Protein Toxins, pp. 427-434, Academic Press London (1984).
Blaustein, R.O. et al., “The N-terminal half of the heavy chan of botulinum type A neurotoxin forms channels in planar phospholipid bilayers,”FEBS Letters 226:115-120, Elsevier Science Publishers B.V. (Biomedical Division) (Dec. 1987).
Fisher, C.E., et al., “Genetic construction and properties of a diptheria toxin-related substance P fusion protein: In vitro destruction of cells bearing substance P receptors,”Proc. Natl. Acad. Sci. USA 93:7341-7345, National Academy of Sciences USA (1996).
Hambleton, P., “Clostridium botulinumtoxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use,”J. Neurol. 239:16-20, Springer-Verlag (1992).
Hay, D.W.P., “Chronic obstructive pulmonary disease: emerging therapies,”Current Opinion in Chemical Biology 4:412-419, Elsevier Science Ltd. (Aug. 2000).
Kielian, M., et al., Mechanisms of Mutations Inhibiting Fusion and Infection by Semliki Forest Virus,J. Cell Biol. 134:863-872, The Rockefeller University Press (1996).
Kihara, A., and Pastan, I., “Analysis of Sequences Required for the Cytotoxic Action of a Chimeric Toxin Composed ofPseudomonasExotoxin and Transforming Growth Factor α,”Bioconjug. Chem. 5:532-538, American Chemical Society (1994).
Kurazono, H., et al., “Minimal Essential Domains Specifying Toxicity of the Light Chains of Tetanus Toxin and Botulinum Neurotoxin Type A,”J. Biol. Chem. 267:14721-14729, American Society for Biochemistry and Molecular Biology, Inc. (1992).
London, E., “Diphtheria toxin: membrane interaction and membrane translocation,”Biochim. Biophys. Acta 1113:25-51, Elsevier Science Publishers B.V. (1992).
Madison, J.M., and Irwin, R.S., “Chronic obstructive pulmonary disease,”The Lancet 352:467-473, The Lancet Publishing Group (Aug. 8, 1998).
Murata, M., et al., “pH-Dependent Membrane Fusion and Vesiculation of Phospholipid Large Unilamellar Vesicles Induced by Amphiphilic Anionic and Cationic Peptides,”Biochemistry 31:1986-1992, American Chemical Society (1992).
Nishiki, T., et al., “Identification of Protein Receptor forClostridium botulinumType B Neurotoxin in Rat Brain Synaptosomes,”J. Biol. Chem. 269:10498-10503, American Society for Biochemistry and Molecular Biology, Inc. (1994).
Nishiki, T., et al., “The high-affinity binding of Clostridium botulinum type B neurotoxin to synaptotagmin II associated with gangliosides GT1b/GD1a,”FEBS Lett. 378:253-257, Federation of European Biochemical Societies (1996).
Poulain, B., et al., “Inhibition of transmitter release by botulinum neurotoxin A. Contributions of various fragments to the intoxication process,”Eur. J. Biochem. 185:197-203, Federation of European Biochemical Societies (1989).
Picard-Maureau, M., et al., “Foamy Virus Envelope Glycoprotein-Mediated Entry Involves a pH-Dependent Fusion Process,”J. Virol. 77:4722-4730, American Society for Microbiology (Apr. 2003).
Plank, C., et al., “The Influence of Endosome-disruptive Peptides on Gene Transfer Using Synthetic Virus-like Gene Transfer Systems,”J. Biol. Chem. 269:12918-12924, The American Society for Biochemistry and Molecular Biology, Inc. (1994).
Prior, T.I., et al., “Translocation Mediated by Domain II ofPseudomonasExotoxin A: Transport of Barnase into the Cytosol,”Biochemistry 31:3555-3559, American Chemical Society (1992).
Rogers, D.F., “Motor control of airway goblet cells and glands,”Respiration Physiology 125:129-144, Elsevier Science B.V. (Mar. 2001).
Rogers, D.F., “Pharmacological regulation of the neuronal control of airway mucus secretion,”Current Opinion in Pharmacology 2:249-255, Elsevier Science Ltd. (Jun. 2002).
Seth, S., et al., “Activation of Fusion by the SER Virus F Protein: a Low-pH-Dependent Paramyxovirus Entry Process,”J. Virol. 77:6520-6527, American Society for Microbiology (Jun. 2003).
Shone et al., “Delivery of Superoxide Dismutase to Neuronal Cells,” U.S. Appl. No. 11/062,471, filed Feb. 22, 2005.
Shone et al., “Recombinant Toxin Fragments,” U.S. Appl. No. 11/077,550, filed Mar. 11, 2005.
Shone et al., “Recombinant Toxin Fragments,” U.S. Appl. No. 10/527,411, filed Mar. 11, 2005.
Shone et al., “Recombinant Toxin Fragments,” U.S. Appl. No. 11/644,010, filed Dec. 22, 2006.
Shone, C.C. et al., “A 50-kDa fragment from the NH2-terminus of the heavy subunit ofClostridium botulinumtype A neurotoxin forms channels in lipid vesicles,”Eur. J. Biochem. 167:175-180, Springer International (Aug. 17, 1987).
Silverman, J.A., et al., “Mutational Analysis of the Helical Hairpin Region of Diphtheria Toxin Transmembrane Domain,”J. Biol. Chem. 269:22524-22532, American Society for Biochemistry and Molecular Biology, Inc. (1994).
Wagner, E., et al., “Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene-transfer vehicle,”Proc. Natl. Acad. Sci. USA 89:7934-7938, National Academy Press (1992).
Yao, Y., et al., “Membrane fusion activity of vesicular stomatitis virus glycoprotein G is induced by low pH but not by heat or denaturant,”Virology 310:319-332, Academic Press (Jun. 2003).
Zhou, L., et al., “Expression and purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP-25 and Neurotoxicity after Reconstitution with the Heavy Chain,”Biochemistry 34:15175-15181, American Chemical Society (1995).
Office Action for U.S. Appl. No. 10/633,698, Quinn, C.P., filed Aug. 5, 2003, mailed on Apr. 29, 2005.
Office Action for U.S. Appl. No. 10/633,698, Quinn, C.P., filed Aug. 5, 2003, mailed on Oct.
Chaddock John
Foster Keith Alan
Quinn Conrad Padraig
Kam Chih-Min
Morris Manning & Martin LLP
Raimund Christopher W.
Syntaxin Ltd.
LandOfFree
Methods and compounds for the treatment of mucus hypersecretion does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compounds for the treatment of mucus hypersecretion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compounds for the treatment of mucus hypersecretion will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4209678